Friday I wrote a post about how differently multiple myeloma can manifest itself in patients--and how different patients react to and follow their myeloma. I featured lifestyle columnist, Danny Parker, as on of my examples. Danny was kind enough to finish what I started in this month's column: Dear Pat and others, I little more
I have received a flood of emails from readers, all including information about clinical trials that do not require a 1.0 M-spike in order to qualify. Thank you! Could my "wish" come true? I may qualify for the before mentioned T cell study after all. A couple of things. First, I never meant to imply
Last year an amazingly knowledgeable oncology nurse from New Jersey, Anne McNeill, blew our on-air support group meeting members away by quickly covering an overwhelming amount of information about the how's and why's of different myeloma tests. So we asked Anne to come back and revisit some of the most important information again; more
I get quite a few questions about serum-free light chain assay testing. When questions like this get technical, I refer readers to an expert. Dr. Rajkumar with Mayo Clinic has written several articles about the topic for the International Myeloma Foundation's (IMF) newsletter. But the best explanation I have ever read is by Dr.
I saved a link back to this Myeloma Beacon story about new ways to measure a multiple myeloma patient's complete response. The article is a bit technical, but there is a lot of good information here for all myeloma patients: New Response Type May Help Determine Multiple Myeloma Patients’ Prognoses By Jessica Langholz - Originally
I'm never sure how many of you actually read the comments from our readers. One reason I started this blog and write here daily is to help share information between myeloma patients. I have always felt you can learn more from other patients than from your physicians or other medical staff. So for those of